Loading company…
Swiss biotech developing multi-specific antibody immunotherapies for inflammation and cancer, with partners including Kaken in Japan.
Founded in 2011 and headquartered in Zurich, Switzerland, Numab Therapeutics AG develops multi-specific antibody immunotherapies for inflammation and cancer using proprietary platforms, including MATCH. Its lead candidate NM26 targets IL-4Ra and IL-31 for atopic dermatitis. The company raised CHF 50.000 mn in Series C funding as of January 9, 2025, led by Cormorant Asset Management and HBM Partners, and Peter Lichtlen is the founder with David Urech as CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in